The investigation, which was initiated on the Competition Authority's own initiative with the Competition Board decision dated 12.01.2011 and numbered 11-03/41-M(a), in order to determine whether there were anti-competitive practices in the diagnostic products and services sector through collusive bidding and/or region/hospital allocation in some tenders where hospitals were the most important buyers, and which concerned the following undertakings was concluded

       Beckman Coulter Biomedikal Ürünler San. Tic. Ltd. Şti.,
       Siemens Healthcare Diagnostik Tic. Ltd. Şti.,
       Roche Diagnostik Sistemleri Ticaret A.Ş.,
       Abbott Laboratuarları İthalat İhracat ve Tic. Ltd. Şti.,
       Mediset Tıbbi Malzemeler İthalat ve Tic. Ltd. Şti.,

and a decision was taken.

As a result of the investigation, the Competition Board decided that sufficient evidence was not gathered to indicate a violation of article 4 of the Act no 4054 through collusive bidding in tenders on diagnostic products and services, and that imposing an administrative fine on the relevant undertakings under article 16 of the Act no 4054 was not necessary.

The final decision dated 29.05.2012 abd numbered 12-28/832-238 was announced to the relevant parties on 05.06.2012.

Please click here for the text of the announcement.